SciELO - Scientific Electronic Library Online

 
vol.52 issue2Carbamazepine kinetics in cardiac patients before and during amiodaronePoliomyelitis in Sergipe (Northeastern Brazil) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Arquivos de Neuro-Psiquiatria

Print version ISSN 0004-282X

Arq. Neuro-Psiquiatr. vol.52 no.2 São Paulo June 1994

http://dx.doi.org/10.1590/S0004-282X1994000200011 

Aumento dos receptores solúveis da interleucina-2 na esclerose múltipla: estudo preliminar em 26 pacientes

 

Elevated levels of soluble interleukin-2 receptors in multiple sclerosis: preliminary report on 26 patients

 

 

Charles P. TilberyI; Eduardo FelipeII; Izabel Maria MotaIII; Morton A. ScheinbergIV

IDisciplina de Neurologia da Faculdade de Ciências Médicas da Santa Casa de São Paulo e da Divisão de Imunologia do Instituto do Câncer Arnaldo Vieira de Carvalho e Instituto Brasileiro de Controle do Câncer: Professor Adjunto de Neurologia
IIDisciplina de Neurologia da Faculdade de Ciências Médicas da Santa Casa de São Paulo e da Divisão de Imunologia do Instituto do Câncer Arnaldo Vieira de Carvalho e Instituto Brasileiro de Controle do Câncer: Professor Instrutor de Neurologia
IIIDisciplina de Neurologia da Faculdade de Ciências Médicas da Santa Casa de São Paulo e da Divisão de Imunologia do Instituto do Câncer Arnaldo Vieira de Carvalho e Instituto Brasileiro de Controle do Câncer: Biomédica da Divisão de Imunologia
IVDisciplina de Neurologia da Faculdade de Ciências Médicas da Santa Casa de São Paulo e da Divisão de Imunologia do Instituto do Câncer Arnaldo Vieira de Carvalho e Instituto Brasileiro de Controle do Câncer: Chefe da Divisão de Imunologia

 

 


RESUMO

Em 26 pacientes com diagnóstico definido de esclerose múltipla foram colhidas amostras de sangue e pesquisados os receptores solúveis de interleucina-2 (RsIL-2). Para tal os pacientes foram divididos em dois grupos: um constituído de 14 pacientes em surto da doença e o outro com 12 pacientes em remissão da moléstia. Além destes, procedeu-se a colheita de material para a mesma pesquisa em 8 pacientes com outras doenças neurológicas. Os resultados demonstraram aumento dos RsIL-2 em 50% dos casos do grupo de pacientes em surto da doença, fato não observado nos demais pacientes dos demais grupos. Estes resultados confirmam a hipótese da ativação de células Tem pacientes em surto de esclerose múltipla, corroborando a hipótese da existência de um desequilíbrio imunológico na doença.

Palavras-chave: esclerose múltipla, surto, interleucina-2 receptor solúvel.


SUMMARY

Serum samples were analysed for interleukin-2 receptors levels (sIL-2R) in 26 patients with definite multiple sclerosis as defined by Poser and col. Three groups of patients form the basis of this study: group I, with 14 patients with clinical evidence of active disease; group II, with 12 patients with clinically stable multiple sclerosis; and group III, with 8 patients with other neurological diseases. Blood was collected by venipuncture and centrifuged. All samples were stored at -20°C until testing. The assay used monoclonal antibodies against epitopes of interleukin-2 receptors. In the wells of a microtiter plate coated with anti-soluble interleukin-2 receptors (Immunotech SA) samples to be measured or standards are incubated in the presence of a second monoclonal antibody conjugated with alkaline phosphatase. The amount of bound enzyme-conjugate is measured by adding a chromogenic substrate. The intensity of the resulting colour is proportional to the sIL-2R concentration present in the sample. Increased serum levels of sIL-2R were found in 7 of 14 patients with active multiple sclerosis (50%), in only 1 of the 12 patients with clinically stable multiple sclerosis and in none of the patients with other neurological diseases.

Key words: multiple sclerosis, active disease, soluble interleukin-2 receptors.


 

 

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

 

 

REFERÊNCIAS

1. Adachi K, Kumamoto T, Araki S. Interlucin-2 receptor levels indicating relapse in multiple sclerosis. Lancet 1989, 1:559-560.         [ Links ]

2. Adachi K, Kumamoto T, Araki S. Elevated soluble interleukin-2 levels in patients with active multiple sclerosis. Ann Neurol 1990, 28:687-691.         [ Links ]

3. Antel JP, Arnason BGW, Medof ME. Suppressor cell function in multiple sclerosis. Ann Neurol 1979, 5:338-342.         [ Links ]

4. Bellamy AS, Calder VL, Feldman M, Davidson AN. The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes. Clin Exp Immunol 1985, 61:248-256.         [ Links ]

5. Capra R, Mattiolo F, Marciano N et al. Significantly higher levels of soluble interleukin-2 in patients with relapsing remitting multiple sclerosis compared with healthy subjects. Arch Neurol 1990, 47:254-259.         [ Links ]

6. Gallo P, Piccino MG, Pagni S et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R and gama-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989, 92:9-15.         [ Links ]

7. Greenberg SJ, Marcon L, Hurwitz BJ, Nelson DL. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med 1988,319:1019-1020.         [ Links ]

8. Hafler DA, Weiner HL. In vivo labelling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol 1987, 22:89-93.         [ Links ]

9. Hartung HP, Hughes RA, Taylor et al. T cell activation in Guillain Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990, 40:215-218.         [ Links ]

10. Hofman FM, von Hanwehr RI, Dinarello CA el al. Immunoregulatory molecules and IL-2 receptor identified in multiple sclerosis brain. J Immunol 1986, 136:3239-3245.         [ Links ]

11. Manoussakis MN, Papadopoulos GK, Drosos A, Moutsopoulos HM. Soluble interleukin-2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopath 1989, 50:321-332.         [ Links ]

12. Merril JE, Mohlstrom C, Uittenboagaart C et al. Response to and production of interleukin-2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J Immunol 1984, 133:1931-1937.         [ Links ]

13. Morimoto C, Hafler DA, Weiner HL. Selective loss of the suppressor inducer T cell subset in progressive multiple sclerosis: analysis with anti-2 H4 monoclonal antibody. N Engl J Med 1987, 316:67-72.         [ Links ]

14. Poser CM, Patty DW, Scheimberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.         [ Links ]

15. Robb BR. Low and high affinity cellular receptors for interleukin-2: implications for the level of Tac antigen. J Exp Med 1987, 160:1126-1130.         [ Links ]

16. Rubin LA. Soluble interleukin-2 receptores are realeased from activated human lymphoid cells in vitro. J Immunol 1985, 135:3172-3175.         [ Links ]

17. Rudick RA, Barna BP. Serum interleukin-2 and soluble interleukin-2 receptor in patients with multiple sclerosis who are experiencing severe fatigue. Arch Neurol 1990, 47:254-255.         [ Links ]

18. Scheimberg MA, Ikejiri M, Silva M, Mota M. Interleukin-2 receptor membrane bound and in soluble form in the acute untreated uveitis. J Rheumatol 1992, 19:1362-1363.         [ Links ]

19. Tilbery CP, Camargo Lima JG, Scheimberg MA, Santos LMB, Yamada FT. Comportamento dos linfócitos T auxiliador e T supressor na esclerose múltipla: estudo preliminar. Rev Paul Med 1984, 102:181 -183.         [ Links ]

20. Tilbery CP, Camargo Lima JG, Scheimberg MA. Aspectos imulogógicos na esclerose múltipla: subpopulacoes de linfócitos e anticorpos anti-linfocitários. Rev Paul Med 1987, 105:134-140.         [ Links ]

21. Trotter JL, Clifford DB, Mclnnis JE et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989, 25:172-178.         [ Links ]

22. Vaisberg M, Scheimberg MA. Simultaneous evaluation of membrane bound and soluble interleukin receptor expression in the blood and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 1990, 8:579-584.         [ Links ]

 

 

Aceite: 18-outubro-1993.

 

 

Estudo da Disciplina de Neurologia da Faculdade de Ciências Médicas da Santa Casa de São Paulo e da Divisão de Imunologia do Instituto do Câncer Arnaldo Vieira de Carvalho e Instituto Brasileiro de Controle do Câncer
Dr. Charles Peter Tilbery - Rua Sampaio Vidal 855 - 01443-001 São Paulo SP - Brasil.